CRIS Current Research Information System

TOVOLI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 10.723
NA - Nord America 9.290
EU - Europa 5.495
Continente sconosciuto - Info sul continente non disponibili 567
AF - Africa 539
SA - Sud America 504
OC - Oceania 14
Totale 27.132
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.051
VN - Vietnam 3.032
CN - Cina 2.746
SG - Singapore 2.632
IT - Italia 1.487
GB - Regno Unito 755
DE - Germania 736
SE - Svezia 600
HK - Hong Kong 563
KR - Corea 370
BD - Bangladesh 365
BR - Brasile 344
IN - India 344
FR - Francia 323
NL - Olanda 273
RU - Federazione Russa 234
IE - Irlanda 231
FI - Finlandia 230
JP - Giappone 169
TG - Togo 149
CH - Svizzera 140
CA - Canada 120
ZA - Sudafrica 117
CI - Costa d'Avorio 97
UA - Ucraina 75
PH - Filippine 73
SC - Seychelles 73
ID - Indonesia 71
AR - Argentina 62
AT - Austria 61
BG - Bulgaria 58
MX - Messico 51
PK - Pakistan 51
TH - Thailandia 51
EE - Estonia 46
TR - Turchia 40
IQ - Iraq 39
JO - Giordania 38
PL - Polonia 37
TW - Taiwan 37
ES - Italia 35
BE - Belgio 33
NG - Nigeria 30
HR - Croazia 25
CL - Cile 23
CO - Colombia 20
EG - Egitto 20
UZ - Uzbekistan 20
EC - Ecuador 17
JM - Giamaica 17
VE - Venezuela 16
LT - Lituania 15
MA - Marocco 15
RO - Romania 15
CR - Costa Rica 13
CZ - Repubblica Ceca 13
GR - Grecia 13
SA - Arabia Saudita 13
DZ - Algeria 11
MK - Macedonia 11
MY - Malesia 11
PT - Portogallo 9
SV - El Salvador 9
AZ - Azerbaigian 8
HN - Honduras 8
KE - Kenya 8
AL - Albania 7
AU - Australia 7
LV - Lettonia 7
PY - Paraguay 7
DK - Danimarca 6
HU - Ungheria 6
LB - Libano 6
PS - Palestinian Territory 6
UY - Uruguay 6
KZ - Kazakistan 5
NP - Nepal 5
PE - Perù 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
ET - Etiopia 4
IL - Israele 3
IR - Iran 3
MD - Moldavia 3
OM - Oman 3
PR - Porto Rico 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
AO - Angola 2
BB - Barbados 2
BF - Burkina Faso 2
CM - Camerun 2
CY - Cipro 2
DO - Repubblica Dominicana 2
KG - Kirghizistan 2
LK - Sri Lanka 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
Totale 26.531
Salva come PNG Salva come JPEG
Città #
Singapore 1.827
Ashburn 1.113
Ho Chi Minh City 743
Hefei 736
Hanoi 699
Fairfield 640
San Jose 620
Southend 597
Chandler 526
Hong Kong 495
Bologna 387
Santa Clara 382
Seoul 326
Woodbridge 296
Council Bluffs 288
Wilmington 279
Seattle 275
Beijing 271
Boardman 263
Houston 256
Dublin 229
Dong Ket 223
Los Angeles 205
Cambridge 203
Princeton 203
New York 183
Helsinki 172
Dallas 161
Ann Arbor 160
Munich 152
Lomé 149
Lauterbourg 146
Da Nang 136
Tokyo 131
Bern 125
Milan 119
Haiphong 113
Abidjan 97
Buffalo 82
Rome 81
Frankfurt am Main 79
São Paulo 78
Redondo Beach 75
Berlin 67
Bengaluru 63
Chicago 61
Westminster 61
Guangzhou 56
Nanjing 54
Turin 53
Shanghai 52
Sofia 52
Johannesburg 50
Padova 50
Amsterdam 45
Orem 43
Jinan 42
Hải Dương 41
Phoenix 41
San Diego 40
Amman 38
Bremen 38
Jakarta 37
Vienna 37
London 36
Can Tho 35
Nuremberg 35
Lappeenranta 34
Shenyang 33
Des Moines 32
Florence 32
Redmond 32
Falkenstein 31
Brussels 30
Lahore 30
Toronto 30
Washington 29
Abeokuta 28
Tianjin 28
Warsaw 28
Biên Hòa 27
Montreal 27
Redwood City 27
Saint Petersburg 27
Tongling 27
Changsha 26
Jacksonville 26
Palermo 24
Shenzhen 24
The Dalles 24
Mexico City 23
Ninh Bình 23
San Francisco 23
Brooklyn 22
Naples 22
Atlanta 21
Nha Trang 21
Vũng Tàu 21
Baghdad 20
Bến Tre 20
Totale 16.320
Salva come PNG Salva come JPEG
Nome #
Serological tests in gluten sensitivity (nonceliac gluten intolerance). 456
Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area 334
Hepatic Steatosis in Patients with Celiac Disease: The Role of Packaged Gluten-Free Foods 320
Monofocal hepatocellular carcinoma: How much does size matter? 302
Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis 284
Imaging-based diagnosis of benign lesions and pseudolesions in the cirrhotic liver 276
Ablation for hepatocellular carcinoma: beyond the standard indications 272
Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: A tale of multiple confounders 262
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 249
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 246
Pattern of macrovascular invasion in hepatocellular carcinoma 246
The duration of the conventional chemoembolization for hepatocellular carcinoma: factors affecting the procedural time 230
Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma 229
Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab–bevacizumab resistance and worse survival in advanced hepatocarcinoma 228
The changing scenario of hepatocellular carcinoma in Italy: an update 227
Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis 227
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 219
Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis 217
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention 216
A case of inflammatory ascites. 215
Current guidelines for the management of celiac disease: A systematic review with comparative analysis 213
Evaluation of Toxicant-Associated Fatty Liver Disease and Liver Neoplastic Progress in Sprague-Dawley Rats Treated with Low Doses of Aflatoxin B1 Alone or in Combination with Extremely Low Frequency Electromagnetic Fields 212
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 211
Celiac disease diagnosed through screening programs in at-risk adults is not associated with worse adherence to the gluten-free diet and might protect from osteopenia/osteoporosis 208
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 207
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial 206
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040 205
Metabolic disorders across hepatocellular carcinoma in Italy 201
Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib 200
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 199
Clinical and diagnostic aspects of gluten related disorders 197
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 195
An uncommon focal liver lesion: Intrahepatic splenosis 193
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma 192
Repeated Previous Transarterial Treatments Negatively Affect Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib 191
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. 190
Combination makes strength: a narrative review of transarterial radioembolization plus immune checkpoint inhibitors for hepatocellular carcinoma 188
Donafenib in hepatocellular carcinoma 188
A relative deficiency of lysosomal acid lypase activity characterizes non-alcoholic fatty liver disease 187
Should patients on levothyroxine therapy be screened for pancreatic cancer? 186
A seroimmunological profile of erosive hand osteoarthritis. 185
Immunotherapy with checkpoint inhibitors for hepatocellular carcinoma: Where are we now? 185
Imaging of combined hepatocellular-cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma 184
Benefits, Open questions and Challenges of the use of Ultrasound in the COVID-19 pandemic eraThe views of a panel of worldwide international experts 184
COVID-19: Has the Liver Been Spared? 184
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 180
New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: A new diagnostic algorithm 179
Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: A multicenter real-life study 179
Presence of Hepatocellular Carcinoma Does Not Affect Course and Response to Anticoagulation of Bland Portal Vein Thrombosis in Cirrhotic Patients 178
Segmental Distribution of Hepatocellular Carcinoma in Cirrhotic Livers 177
Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free diet: beyond traditional metabolic factors 177
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib 177
Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma 176
Imaging of colorectal liver metastases: New developments and pending issues 176
Risk of Drop-Out from Follow-Up Evaluations for Celiac Disease: Is It Similar for All Patients? 175
Cholangiocarcinoma: From risk to prevention? 174
Deamidated gliadin Peptide antibodies as a routine test for celiac disease: a prospective analysis. 171
Antibodies to deamidated gliadin peptides: an accurate predictor of coeliac disease in infancy. 170
More therapeutic alternatives for chronic idiopathic urticaria? 169
Thrombotic thrombocytopenic purpura mimicking an acute meningoencephalitis. 168
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients 166
From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma 165
TKIs in combination with immunotherapy for hepatocellular carcinoma 165
null 164
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster 164
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 163
Outcome of hepatic resection for HCC in ideal and non-ideal candidates 161
Eosinophilic granulomatosis with polyangiitis of the major salivary glands: a case of sialadenitis in a young patient. 161
Clinical and immunological features of celiac disease in patients with Type 1 diabetes mellitus. 161
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 160
Systemic treatments for hepatocellular carcinoma: challenges and future perspectives 160
Autoimmune liver disorders and small-vessel vasculitis:four case reports and review of the literature 159
Lung Ultrasound Is Often, but Not Always, Normal in Healthy Subjects: Considerations for {COVID}-19 Pandemic 159
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments 157
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. 156
Treatment of combined hepatocellular and cholangiocarcinoma 156
An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib 155
Rheumatoid arthritis: New monoclonal antibodies 154
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma (Targeted Oncology, (2020), 15, 6, (773-785), 10.1007/s11523-020-00757-3) 154
Experience with regorafenib in the treatment of hepatocellular carcinoma 154
Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease 152
Exploring occupational toxicant exposures in patients with metabolic dysfunction-associated steatotic liver disease: A prospective pilot study 152
Advancements in immunotherapy for hepatocellular carcinoma 148
Old and new serological tests for celiac disease screening. 146
Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma 146
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial 146
Effect of gluten free diet on immune response to gliadin in patients with non-celiac gluten sensitivity. 145
A new horizon in the prevention of the postembolization syndrome after transcatheter arterial chemoembolization for hepatocellular carcinoma 144
Fulminant type 1 autoimmune hepatitis in a recently diagnosed celiac disease patient. 143
Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5) 142
Radiological Features of Microvascular Invasion of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease 141
Anti-neutrophil cytoplasm antibodies (ANCA) in autoimmune diseases: A matter of laboratory technique and clinical setting 141
TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma 138
Nailfold capillaroscopy in primary biliary cirrhosis: a useful tool for the early diagnosis of scleroderma. 135
The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy 135
Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis 135
Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019 134
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 134
Autoantibodies to speckled protein family in primary biliary cholangitis 134
Telomerase reactivation is associated with hepatobiliary and pancreatic cancers 133
Totale 18.790
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.329
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.329
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.926 0 42 94 108 175 112 50 167 106 154 646 272
2022/20232.589 230 357 126 305 164 212 164 133 441 67 170 220
2023/20241.049 49 141 76 77 112 216 84 86 65 73 48 22
2024/20254.410 168 424 415 295 515 215 545 176 108 317 348 884
2025/202612.326 1.107 1.202 948 810 1.045 483 1.702 444 2.342 886 632 725
2026/2027894 523 371 0 0 0 0 0 0 0 0 0 0
Totale 27.132